Navigation Links
Innocoll, Inc. Files 510 (k) Application for CollaRx Lidocaine Sponge
Date:3/31/2009

eave-behind implant currently in phase III development for the prevention of surgical site infections in patients or surgeries at higher risk of infection.

About Innocoll, Inc.

Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx(R) and Liquicoll(R). Innocoll has licensed its US marketing rights to its lead product, CollaRx GENTAMICIN SURGICAL IMPLANT to a division of Baxter International (NYSE: BAX) The product is currently in phase 3 development in the US for the prevention of surgical site infections. It is approved for sale in 49 countries in Europe, Latin America, Middle East, Africa and Asia. Other late stage pharmaceutical products in Innocoll's development pipeline include CollaRx Gentamicin Topical for the treatment and prevention of infected diabetic foot ulcers and CollaRx Bupivacaine Implant for the management of post-operative pain, both of which are currently in Phase 2 development. For more information, please visit www.innocollinc.com.


'/>"/>
SOURCE Innocoll, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
2. Renowned Stem Cell Researcher Files Study Results With Stemedica
3. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
4. Investor Group Files Complaint With Irish Office of the Director of Corporate Enforcement Against Named Directors of Trinity Biotech
5. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
6. Orcrist Bio Inc. Files with European Competent Authority for a Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750
7. Tigris Pharmaceuticals Files IND Application for GGTI-2418
8. Panda Ethanols Hereford, Texas Subsidiary Files Voluntary Chapter 11
9. Stem Cell Innovations, Inc., Files New Patent Application
10. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
11. ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)...  Tikcro Technologies Ltd. (OTCQB: TIKRF) today reported results ... Aviv Boim , CEO of Tikcro ... generate functional specific antibodies, targeting identified cancer immune checkpoints. ... by the development progress. We are excited to invest ... immune checkpoints gain clinical acceptance for cancer treatment."Net loss ...
(Date:5/27/2015)... BETHESDA, Md. , May 27, 2015  Northwest ... biotechnology company developing DCVax® personalized immune therapies for cancer, ... Chief Technical Officer of the Company, will be making ... Annual Meeting in Chicago on ... CDT, at the Industry Expert Theater in McCormick Place. ...
(Date:5/27/2015)... 2015  RXi Pharmaceuticals Corporation (NASDAQ: RXII ... developing innovative therapies primarily in the areas of ... status of the Company,s Series A and Series ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO At March ... of Series A Preferred Stock and Series A-1 ...
(Date:5/26/2015)... Regenestem Network has announced the grand opening ... Argentina. The clinic will be lead by Silvina Pastrana, ... a multidisciplinary team of medical professionals who specialize in ... office. , The new Regenestem Network members plan ... in cellular therapies, and establish Regenestem protocols to isolate ...
Breaking Biology Technology:Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3
... ReportsnReports announces it will carry , , Daptomycin ... Browse the complete , , Daptomycin - Comprehensive patent,search ... Market Research,Reports Browse All ... Eliminate unnecessary risk with the industry benchmark in,comprehensive patent information. ...
... nation,s long-term clean-energy future, but the technology has come ... Fukushima disaster. Indeed, many nations have called for checks ... safely. In the United States, about 20 ... the electricity from emission-free sources, including renewable technologies and ...
... Cebix Incorporated announced today that preclinical data for ... demonstrated a half-life of three days as compared to ... in nerve conduction velocity, a measure of the rate ... an animal model of diabetic peripheral neuropathy. Additionally, clinical ...
Cached Biology Technology:ReportsnReports - Daptomycin - Comprehensive Patent Search 2ReportsnReports - Daptomycin - Comprehensive Patent Search 3ReportsnReports - Daptomycin - Comprehensive Patent Search 4ReportsnReports - Daptomycin - Comprehensive Patent Search 5Berkeley scientists pioneer nanoscale nuclear materials testing capability 2Cebix's Long-Acting C-Peptide Ersatta™ has Potential in Multiple Chronic Complications of Diabetes 2Cebix's Long-Acting C-Peptide Ersatta™ has Potential in Multiple Chronic Complications of Diabetes 3
(Date:5/21/2015)... 21, 2015 The Sync Project™ , ... for health, today announced a collaborative partnership with ... will center on collaboration on original research, joint course ... in the collaboration, The Sync Project and BerkleeICE are ... Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... Research and Markets ( ... the  "Genetic Testing Market Outlook 2018"  report ... ,A recent report, Genetic Testing Market Outlook ... current and future genetic testing market. A ... principles and types are covered in this ...
(Date:5/11/2015)... DAYTON, Ohio , May 11, 2015  Through a ... Ohio had a strong showing at AUVSI,s ... . These representatives of Ohio,s UAS ... domestic and abroad from all points along the UAS ecosystem. ... Dayton Development Coalition,s (DDC) Vice President for Aerospace Rich ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Genetic Testing Market Outlook 2018 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... and ecological sustainability of biofuels and the impact of ... America will take place on Friday, Dec. 5, in ... Neotropical Forests: Trends, Implications and Emerging Alternatives, is sponsored ... the Program in Native Species Reforestation, both joint programs ...
... Associated Professor, DSc Barbara Ann Halkier, Department of ... Life Sciences, University of Copenhagen, has been granted ... award for her excellent research into secondary metabolites, ... plants. In particular, her research has focused ...
... Company Experiences Record Revenue Growth from Operations in Third Quarter , ... bioMETRX, Inc. (OTC Bulletin Board: BMRX), a leading developer of consumer-based ... ending September 30, 2008. , , ... 430% increase over second quarter revenues of $100,000. , ...
Cached Biology News:Conference to explore sustainability of biofuels 2The Danisco Award 2008 goes to D.Sc. Barbara Ann Halkier from Faculty of Life Sciences, Copenhagen 2bioMETRX, Inc. Highlights 3rd Quarter 2008 Financial Results 2
Mouse monoclonal antibody raised against a partial recombinant AAAS. NCBI Entrez Gene ID = AAAS...
Rabbit polyclonal to MCP2 ( Abpromise for all tested applications). entrezGeneID: 6355 SwissProtID: P49873...
... A sensitive and high speed homogeneous ... phosphatase activity and for screening of inhibitors ... kit is based on a fluorescence superquenching ... radioactive label. The universal platform provides flexibility ...
... PowerPac 3000 power supply, 220-240 V, is ... liquid-phase isoelectric focusing (IEF). The system includes ... (60 ml) focusing chambers, chassis, harvesting apparatus, ... supply, 10 ml Bio-Lyte ampholytes (pH 3-10), ...
Biology Products: